Table Info

Table 2.

Summary of evidence for most promising methylation biomarkers for diagnosis of CRC in blood (sensitivity > 75%)

Biomarker gene(s)	Sensitivity (%)	Specificity (%)	Reference
ALX4	80–83	41–70	[55, 56]
ALX4, BMP3, NPTX2, RARB, SDC2, SEPT9, VIM	91	73	[57]
ALX4, SEPT9, TMEFF2	81	90	[32, 55]
APC, MGMT, RASSF2A, WIF1	87	92	[22]
BCAT1, IKZF1	66–77	92–94	[58]
C9orf50, CLIP4, KCNQ5	85	99	[59]
C9orf50, KCNJ12, ZNF132, TWIST1	80	97	[60]
CYCD2, HIC1, PAX5, RASSF1A, RB1, SRBC	84	68	[61]
EFHD1	79	78	[29]
EFDH1, PPP1R3C	90	64	[29]
NPY	87	80	[62]
PPP1R3C	79–81	81	[29]
PRIMA1	81	73	[49]
PRIMA1, SDC2, SFRP1, SFRP2	92	97	[49]
RASSF2	93	53	[61]
SDC2	87–89	95–97	[49, 50]
SDC2, SEPT9	86–89	87–93	[63–66]
SDC2, SEPT9, SFRP2	94	89	[67]
SEPT9	75–90	92–97	[32, 33, 68–72]
SEPT9, CEA	86	96	[73]
SFRP1	80	92	[74]
SPG20	81	97	[75]

ALX4: ALX homeobox 4; NPTX2: neuronal pentraxin 2; TMEFF2: transmembrane protein with EGF like and two follistatin like domains 2; KCNJ12: potassium inwardly rectifying channel subfamily J member 12; TWIST1: twist family bHLH transcription factor 1; CYCD2: predicted protein; HIC1: HIC ZBTB transcriptional repressor 1; PAX5: paired box 5; RB1: RB transcriptional corepressor 1; SRBC: CD2 molecule; PPP1R3C: protein phosphatase 1 regulatory subunit 3C; NPY: neuropeptide Y

Declarations

Author contributions

JY: Data curation, Writing—original draft. JZ and WD: Conceptualization, Investigation, Writing—review & editing. All authors revised the manuscript and approved the final version of it.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

The work was supported by the National Natural Science Foundation of China [81974313]; Postdoctoral Science Foundation of China [2019M651930]; the Natural Science Foundation of Jiangsu Commission of Health [M2020065]; the Science and Technology Program of Nantong [JC22022040]; Nantong Commission of Health Research Fund Project [MA2021004]; Jiangsu Provincial Research Hospital [YJXYY202204]; and Jiangsu Provincial Medical Key Discipline [ZDXK202240]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. [DOI] [PubMed]

Goel A, Boland CR. Epigenetics of colorectal cancer. Gastroenterology. 2012;143:1442–60.E1. [DOI] [PubMed] [PMC]

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. [DOI] [PubMed]

Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. Science. 2017;357:eaal2380. [DOI] [PubMed] [PMC]

Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut. 2008;57:941–50. [DOI] [PubMed]

Ryan E, Sheahan K, Creavin B, Mohan HM, Winter DC. The current value of determining the mismatch repair status of colorectal cancer: a rationale for routine testing. Crit Rev Oncol Hematol. 2017;116:38–57. [DOI] [PubMed]

Liu X, Fu J, Bi H, Ge A, Xia T, Liu Y, et al. DNA methylation of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer patients. BMC Cancer. 2019;19:1212. [DOI] [PubMed] [PMC]

Cabrera-Mulero A, Crujeiras AB, Izquierdo AG, Torres E, Ayers D, Casanueva FF, et al. Novel SFRP2 DNA methylation profile following neoadjuvant therapy in colorectal cancer patients with different grades of BMI. J Clin Med. 2019;8:1041. [DOI] [PubMed] [PMC]

Wang DR, Tang D. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol. 2008;14:524–31. [DOI] [PubMed] [PMC]

10.

Kang B, Lee HS, Jeon SW, Park SY, Choi GS, Lee WK, et al. Progressive alteration of DNA methylation of Alu, MGMT, MINT2, and TFPI2 genes in colonic mucosa during colorectal cancer development. Cancer Biomark. 2021;32:231–6. [DOI] [PubMed]

11.

Freitas M, Ferreira F, Carvalho S, Silva F, Lopes P, Antunes L, et al. A novel DNA methylation panel accurately detects colorectal cancer independently of molecular pathway. J Transl Med. 2018;16:45. [DOI] [PubMed] [PMC]

12.

Sugai T, Yoshida M, Eizuka M, Uesugii N, Habano W, Otsuka K, et al. Analysis of the DNA methylation level of cancer-related genes in colorectal cancer and the surrounding normal mucosa. Clin Epigenetics. 2017;9:55. [DOI] [PubMed] [PMC]

13.

Stuckel AJ, Zhang W, Zhang X, Zeng S, Dougherty U, Mustafi R, et al. Enhanced CXCR4 expression associates with increased gene body 5-hydroxymethylcytosine modification but not decreased promoter methylation in colorectal cancer. Cancers (Basel). 2020;12:539. Erratum in: Cancers (Basel). 2020;12:3104. [DOI] [PubMed] [PMC]

14.

Mikhaleva LM, Vandysheva RA, Midiber KY, Vasyukova OA, Pechnikova VV, Patsap OI, et al. Colorectal serrated lesions: a current view on clinical, morphological, molecular, and genetic diagnostic criteria. Curr Med Chem. 2021;28:8496–516. [DOI] [PubMed]

15.

De Palma FDE, D’Argenio V, Pol J, Kroemer G, Maiuri MC, Salvatore F. The molecular hallmarks of the serrated pathway in colorectal cancer. Cancers (Basel). 2019;11:1017. [DOI] [PubMed] [PMC]

16.

Graule J, Uth K, Fischer E, Centeno I, Galván JA, Eichmann M, et al. CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway. Clin Epigenetics. 2018;10:120. [DOI] [PubMed] [PMC]

17.

Gu S, Lin S, Ye D, Qian S, Jiang D, Zhang X, et al. Genome-wide methylation profiling identified novel differentially hypermethylated biomarker MPPED2 in colorectal cancer. Clin Epigenetics. 2019;11:41. [DOI] [PubMed] [PMC]

18.

Li D, Zhang L, Fu J, Huang H, Sun S, Zhang D, et al. SCTR hypermethylation is a diagnostic biomarker in colorectal cancer. Cancer Sci. 2020;111:4558–66. [DOI] [PubMed] [PMC]

19.

Chen B, Scurrah CR, McKinley ET, Simmons AJ, Ramirez-Solano MA, Zhu X, et al. Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. Cell. 2021;184:6262–80.E26. [DOI] [PubMed] [PMC]

20.

Becker WR, Nevins SA, Chen DC, Chiu R, Horning AM, Guha TK, et al. Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer. Nat Genet. 2022;54:985–95. [DOI] [PubMed] [PMC]

21.

Lind GE, Danielsen SA, Ahlquist T, Merok MA, Andresen K, Skotheim RI, et al. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer. 2011;10:85. [DOI] [PubMed] [PMC]

22.

Lee BB, Lee EJ, Jung EH, Chun HK, Chang DK, Song SY, et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res. 2009;15:6185–91. [DOI] [PubMed]

23.

Jamialahmadi K, Azghandi M, Javadmanesh A, Zardadi M, Shams Davodly E, Kerachian MA. A DNA methylation panel for high performance detection of colorectal cancer. Cancer Genet. 2021;252:64–72. [DOI] [PubMed]

24.

Azuara D, Rodriguez-Moranta F, de Oca J, Soriano-Izquierdo A, Mora J, Guardiola J, et al. Novel methylation panel for the early detection of colorectal tumors in stool DNA. Clin Colorectal Cancer. 2010;9:168–76. [DOI] [PubMed]

25.

Zou H, Allawi H, Cao X, Domanico M, Harrington J, Taylor WR, et al. Quantification of methylated markers with a multiplex methylation-specific technology. Clin Chem. 2012;58:375–83. [DOI] [PubMed]

26.

Michailidi C, Theocharis S, Tsourouflis G, Pletsa V, Kouraklis G, Patsouris E, et al. Expression and promoter methylation status of hMLH1, MGMT, APC, and CDH1 genes in patients with colon adenocarcinoma. Exp Biol Med (Maywood). 2015;240:1599–605. [DOI] [PubMed] [PMC]

27.

Li J, Chen C, Bi X, Zhou C, Huang T, Ni C, et al. DNA methylation of CMTM3, SSTR2, and MDFI genes in colorectal cancer. Gene. 2017;630:1–7. [DOI] [PubMed]

28.

Rademakers G, Massen M, Koch A, Draht MX, Buekers N, Wouters KAD, et al. Identification of DNA methylation markers for early detection of CRC indicates a role for nervous system-related genes in CRC. Clin Epigenetics. 2021;13:80. [DOI] [PubMed] [PMC]

29.

Takane K, Midorikawa Y, Yagi K, Sakai A, Aburatani H, Takayama T, et al. Aberrant promoter methylation of PPP1R3C and EFHD1 in plasma of colorectal cancer patients. Cancer Med. 2014;3:1235–45. [DOI] [PubMed] [PMC]

30.

Barault L, Amatu A, Siravegna G, Ponzetti A, Moran S, Cassingena A, et al. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut. 2018;67:1995–2005. [DOI] [PubMed] [PMC]

31.

Xiao W, Zhao H, Dong W, Li Q, Zhu J, Li G, et al. Quantitative detection of methylated NDRG4 gene as a candidate biomarker for diagnosis of colorectal cancer. Oncol Lett. 2015;9:1383–7. [DOI] [PubMed] [PMC]

32.

He Q, Chen HY, Bai EQ, Luo YX, Fu RJ, He YS, et al. Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer. Cancer Genet Cytogenet. 2010;202:1–10. [DOI] [PubMed]

33.

Tóth K, Wasserkort R, Sipos F, Kalmár A, Wichmann B, Leiszter K, et al. Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA. PLoS One. 2014;9:e115415. [DOI] [PubMed] [PMC]

34.

Qi J, Zhu YQ, Luo J, Tao WH. Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor. World J Gastroenterol. 2006;12:7113–7. [DOI] [PubMed] [PMC]

35.

Samaei NM, Yazdani Y, Alizadeh-Navaei R, Azadeh H, Farazmandfar T. Promoter methylation analysis of WNT/β-catenin pathway regulators and its association with expression of DNMT1 enzyme in colorectal cancer. J Biomed Sci. 2014;21:73. [DOI] [PubMed] [PMC]

36.

Tang D, Liu J, Wang DR, Yu HF, Li YK, Zhang JQ. Diagnostic and prognostic value of the methylation status of secreted frizzled-related protein 2 in colorectal cancer. Clin Invest Med. 2011;34:E88–95. [DOI] [PubMed]

37.

El Azzouzi M, El Ahanidi H, Hafidi Alaoui C, Chaoui I, Benbacer L, Tetou M, et al. Evaluation of DNA methylation in promoter regions of hTERT, TWIST1, VIM and NID2 genes in Moroccan bladder cancer patients. Cancer Genet. 2022;260-261:41–5. [DOI] [PubMed]

38.

Li D, Zhang L, Fu J, Huang H, Liu Y, Zhu L, et al. Discovery and validation of tissue-specific DNA methylation as noninvasive diagnostic markers for colorectal cancer. Clin Epigenetics. 2022;14:102. [DOI] [PubMed] [PMC]

39.

Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst. 2008;100:1734–8. [DOI] [PubMed] [PMC]

40.

Barchitta M, Quattrocchi A, Maugeri A, Vinciguerra M, Agodi A. LINE-1 hypomethylation in blood and tissue samples as an epigenetic marker for cancer risk: a systematic review and meta-analysis. PLoS One. 2014;9:e109478. [DOI] [PubMed] [PMC]

41.

Pedersen SK, Symonds EL, Baker RT, Murray DH, McEvoy A, Van Doorn SC, et al. Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia. BMC Cancer. 2015;15:654. [DOI] [PubMed] [PMC]

42.

Symonds EL, Pedersen SK, Baker RT, Murray DH, Gaur S, Cole SR, et al. A blood test for methylated BCAT1 and IKZF1 vs. a fecal immunochemical test for detection of colorectal neoplasia. Clin Transl Gastroenterol. 2016;7:e137. [DOI] [PubMed] [PMC]

43.

Fu B, Yan P, Zhang S, Lu Y, Pan L, Tang W, et al. Cell-free circulating methylated SEPT9 for noninvasive diagnosis and monitoring of colorectal cancer. Dis Markers. 2018;2018:6437104. [DOI] [PubMed] [PMC]

44.

Song L, Peng X, Li Y, Xiao W, Jia J, Dong C, et al. The SEPT9 gene methylation assay is capable of detecting colorectal adenoma in opportunistic screening. Epigenomics. 2017;9:599–610. [DOI] [PubMed]

45.

Weirich CS, Erzberger JP, Barral Y. The septin family of GTPases: architecture and dynamics. Nat Rev Mol Cell Biol. 2008;9:478–89. [DOI] [PubMed]

46.

Ma ZY, Chan CSY, Lau KS, Ng L, Cheng YY, Leung WK. Application of droplet digital polymerase chain reaction of plasma methylated septin 9 on detection and early monitoring of colorectal cancer. Sci Rep. 2021;11:23446. [DOI] [PubMed] [PMC]

47.

Pu W, Qian F, Liu J, Shao K, Xiao F, Jin Q, et al. Targeted bisulfite sequencing reveals DNA methylation changes in zinc finger family genes associated with KRAS mutated colorectal cancer. Front Cell Dev Biol. 2021;9:759813. [DOI] [PubMed] [PMC]

48.

Pedersen SK, Baker RT, McEvoy A, Murray DH, Thomas M, Molloy PL, et al. A two-gene blood test for methylated DNA sensitive for colorectal cancer. PLoS One. 2015;10:e0125041. [DOI] [PubMed] [PMC]

49.

Barták BK, Kalmár A, Péterfia B, Patai ÁV, Galamb O, Valcz G, et al. Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples. Epigenetics. 2017;12:751–63. [DOI] [PubMed] [PMC]

50.

Oh T, Kim N, Moon Y, Kim MS, Hoehn BD, Park CH, et al. Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. J Mol Diagn. 2013;15:498–507. [DOI] [PubMed]

51.

Han YD, Oh TJ, Chung TH, Jang HW, Kim YN, An S, et al. Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA. Clin Epigenetics. 2019;11:51. [DOI] [PubMed] [PMC]

52.

Oh TJ, Oh HI, Seo YY, Jeong D, Kim C, Kang HW, et al. Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Clin Epigenetics. 2017;9:126. [DOI] [PubMed] [PMC]

53.

Song BP, Jain S, Lin SY, Chen Q, Block TM, Song W, et al. Detection of hypermethylated vimentin in urine of patients with colorectal cancer. J Mol Diagn. 2012;14:112–9. [DOI] [PubMed] [PMC]

54.

Ahlquist DA, Taylor WR, Mahoney DW, Zou H, Domanico M, Thibodeau SN, et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol. 2012;10:272–7.E1. [DOI] [PubMed] [PMC]

55.

Tänzer M, Balluff B, Distler J, Hale K, Leodolter A, Röcken C, et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One. 2010;5:e9061. [DOI] [PubMed] [PMC]

56.

Ebert MP, Model F, Mooney S, Hale K, Lograsso J, Tonnes-Priddy L, et al. Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology. 2006;131:1418–30. [DOI] [PubMed]

57.

Rasmussen SL, Krarup HB, Sunesen KG, Johansen MB, Stender MT, Pedersen IS, et al. Hypermethylated DNA, a circulating biomarker for colorectal cancer detection. PLoS One. 2017;12:e0180809. [DOI] [PubMed] [PMC]

58.

Symonds EL, Pedersen SK, Murray DH, Jedi M, Byrne SE, Rabbitt P, et al. Circulating tumour DNA for monitoring colorectal cancer—a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection. Clin Epigenetics. 2018;10:63. [DOI] [PubMed] [PMC]

59.

Jensen SØ, Øgaard N, Ørntoft MW, Rasmussen MH, Bramsen JB, Kristensen H, et al. Novel DNA methylation biomarkers show high sensitivity and specificity for blood-based detection of colorectal cancer—a clinical biomarker discovery and validation study. Clin Epigenetics. 2019;11:158. [DOI] [PubMed] [PMC]

60.

Zhang Y, Wu Q, Xu L, Wang H, Liu X, Li S, et al. Sensitive detection of colorectal cancer in peripheral blood by a novel methylation assay. Clin Epigenetics. 2021;13:90. [DOI] [PubMed] [PMC]

61.

Cassinotti E, Melson J, Liggett T, Melnikov A, Yi Q, Replogle C, et al. DNA methylation patterns in blood of patients with colorectal cancer and adenomatous colorectal polyps. Int J Cancer. 2012;131:1153–7. [DOI] [PubMed] [PMC]

62.

Roperch JP, Incitti R, Forbin S, Bard F, Mansour H, Mesli F, et al. Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer. BMC Cancer. 2013;13:566. [DOI] [PubMed] [PMC]

63.

Chen Z, Zhao G, Wang K, Wang X, Ma Y, Xiong S, et al. Blood leukocytes methylation levels analysis indicate methylated plasma test is a promising tool for colorectal cancer early detection. J Cancer. 2021;12:3678–85. [DOI] [PubMed] [PMC]

64.

Singh MK, Pauza CD. Extrachromosomal human immunodeficiency virus type 1 sequences are methylated in latently infected U937 cells. Virology. 1992;188:451–8. [DOI] [PubMed]

65.

Chen Y, Wang Z, Zhao G, Sun C, Ma Y, Zhang L, et al. Performance of a novel blood-based early colorectal cancer screening assay in remaining serum after the blood biochemical test. Dis Markers. 2019;2019:5232780. [DOI] [PubMed] [PMC]

66.

Zhao G, Li H, Yang Z, Wang Z, Xu M, Xiong S, et al. Multiplex methylated DNA testing in plasma with high sensitivity and specificity for colorectal cancer screening. Cancer Med. 2019;8:5619–28. [DOI] [PubMed] [PMC]

67.

Liu C, Xu L, Li W, Jie M, Xue W, Yu W. Multiple biomarker-combined screening for colorectal cancer based on bisulfate conversion-free detection of fecal DNA methylation. Biomed Res Int. 2021;2021:1479748. [DOI] [PubMed] [PMC]

68.

Wu D, Zhou G, Jin P, Zhu J, Li S, Wu Q, et al. Detection of colorectal cancer using a simplified SEPT9 gene methylation assay is a reliable method for opportunistic screening. J Mol Diagn. 2016;18:535–45. [DOI] [PubMed]

69.

Lofton-Day C, Model F, Devos T, Tetzner R, Distler J, Schuster M, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem. 2008;54:414–23. [DOI] [PubMed]

70.

deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem. 2009;55:1337–46. [DOI] [PubMed]

71.

Warren JD, Xiong W, Bunker AM, Vaughn CP, Furtado LV, Roberts WL, et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 2011;9:133. [DOI] [PubMed] [PMC]

72.

He N, Song L, Kang Q, Jin P, Cai G, Zhou J, et al. The pathological features of colorectal cancer determine the detection performance on blood ctDNA. Technol Cancer Res Treat. 2018;17:1533033818791794. [DOI] [PubMed] [PMC]

73.

Song L, Jia J, Peng X, Xiao W, Li Y. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: a meta-analysis. Sci Rep. 2017;7:3032. [DOI] [PubMed] [PMC]

74.

Bedin C, Enzo MV, Del Bianco P, Pucciarelli S, Nitti D, Agostini M. Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients. Int J Cancer. 2017;140:1888–98. [DOI] [PubMed]

75.

Rezvani N, Alibakhshi R, Vaisi-Raygani A, Bashiri H, Saidijam M. Detection of SPG20 gene promoter-methylated DNA, as a novel epigenetic biomarker, in plasma for colorectal cancer diagnosis using the MethyLight method. Oncol Lett. 2017;13:3277–84. [DOI] [PubMed] [PMC]

76.

Ahlquist DA, Zou H, Domanico M, Mahoney DW, Yab TC, Taylor WR, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology. 2012;142:248–56. [DOI] [PubMed] [PMC]

77.

Ned RM, Melillo S, Marrone M. Fecal DNA testing for colorectal cancer screening: the ColoSure™ test. PLoS Curr. 2011;3:RRN1220. [DOI] [PubMed] [PMC]

78.

Hibi K, Goto T, Kitamura YH, Yokomizo K, Sakuraba K, Shirahata A, et al. Methylation of TFPI2 gene is frequently detected in advanced well-differentiated colorectal cancer. Anticancer Res. 2010;30:1205–7. [PubMed]

79.

Glöckner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 2009;69:4691–9. [DOI] [PubMed] [PMC]

80.

Liu X, Wen J, Li C, Wang H, Wang J, Zou H. High-yield methylation markers for stool-based detection of colorectal cancer. Dig Dis Sci. 2020;65:1710–9. [DOI] [PubMed]

81.

Chu D, Zhang Z, Zhou Y, Li Y, Zhu S, Zhang J, et al. NDRG4, a novel candidate tumor suppressor, is a predictor of overall survival of colorectal cancer patients. Oncotarget. 2015;6:7584–96. [DOI] [PubMed] [PMC]

82.

Müller D, Győrffy B. DNA methylation-based diagnostic, prognostic, and predictive biomarkers in colorectal cancer. Biochim Biophys Acta Rev Cancer. 2022;1877:188722. [DOI] [PubMed]

83.

Park SK, Baek HL, Yu J, Kim JY, Yang HJ, Jung YS, et al. Is methylation analysis of SFRP2, TFPI2, NDRG4, and BMP3 promoters suitable for colorectal cancer screening in the Korean population? Intest Res. 2017;15:495–501. [DOI] [PubMed] [PMC]

84.

Leung WK, To KF, Man EP, Chan MW, Hui AJ, Ng SS, et al. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am J Gastroenterol. 2007;102:1070–6. [DOI] [PubMed]

85.

Li WH, Zhang H, Guo Q, Wu XD, Xu ZS, Dang CX, et al. Detection of SNCA and FBN1 methylation in the stool as a biomarker for colorectal cancer. Dis Markers. 2015;2015:657570. [DOI] [PubMed] [PMC]

86.

Lu H, Huang S, Zhang X, Wang D, Zhang X, Yuan X, et al. DNA methylation analysis of SFRP2, GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in fecal DNA. Oncol Lett. 2014;8:1751–6. [DOI] [PubMed] [PMC]

87.

Huang ZH, Li LH, Yang F, Wang JF. Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol. 2007;13:950–4. [DOI] [PubMed] [PMC]

88.

Zhang X, Wan S, Yu Y, Ruan W, Wang H, Xu L, et al. Identifying potential DNA methylation markers in early-stage colorectal cancer. Genomics. 2020;112:3365–73. [DOI] [PubMed]

89.

Lidgard GP, Domanico MJ, Bruinsma JJ, Light J, Gagrat ZD, Oldham-Haltom RL, et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol. 2013;11:1313–8. [DOI] [PubMed]

90.

Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370:1287–97. [DOI] [PubMed]

91.

Baek YH, Chang E, Kim YJ, Kim BK, Sohn JH, Park DI. Stool methylation-specific polymerase chain reaction assay for the detection of colorectal neoplasia in Korean patients. Dis Colon Rectum. 2009;52:1452–9. [DOI] [PubMed]

92.

Liu Y, Zhao G, Miao J, Li H, Ma Y, Liu X, et al. Performance comparison between plasma and stool methylated SEPT9 tests for detecting colorectal cancer. Front Genet. 2020;11:324. [DOI] [PubMed] [PMC]

93.

Zhang W, Bauer M, Croner RS, Pelz JO, Lodygin D, Hermeking H, et al. DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene. Dis Colon Rectum. 2007;50:1618–27. [DOI] [PubMed]

94.

Li M, Chen WD, Papadopoulos N, Goodman SN, Bjerregaard NC, Laurberg S, et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol. 2009;27:858–63. [DOI] [PubMed] [PMC]

95.

Xiao Z, Li B, Wang G, Zhu W, Wang Z, Lin J, et al. Validation of methylation-sensitive high-resolution melting (MS-HRM) for the detection of stool DNA methylation in colorectal neoplasms. Clin Chim Acta. 2014;431:154–63. [DOI] [PubMed]

96.

Shao K, Pu W, Zhang J, Guo S, Qian F, Glurich I, et al. DNA hypermethylation contributes to colorectal cancer metastasis by regulating the binding of CEBPB and TFCP2 to the CPEB1 promoter. Clin Epigenetics. 2021;13:89. [DOI] [PubMed] [PMC]

97.

Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, et al. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol. 2018;29:139–44. Erratum in: Ann Oncol. 2019;30:495. [DOI] [PubMed] [PMC]

98.

Wang Y, He T, Herman JG, Linghu E, Yang Y, Fuks F, et al. Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth. Clin Epigenetics. 2017;9:115. Erratum in: Clin Epigenetics. 2018;10:36. [DOI] [PubMed] [PMC]

99.

Wong CC, Xu J, Bian X, Wu JL, Kang W, Qian Y, et al. In colorectal cancer cells with mutant KRAS, SLC25A22-mediated glutaminolysis reduces DNA demethylation to increase WNT signaling, stemness, and drug resistance. Gastroenterology. 2020;159:2163–80.E6. [DOI] [PubMed]

100.

Antelo M, Balaguer F, Shia J, Shen Y, Hur K, Moreira L, et al. A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. PLoS One. 2012;7:e45357. [DOI] [PubMed] [PMC]

101.

Kawakami K, Matsunoki A, Kaneko M, Saito K, Watanabe G, Minamoto T. Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer. Cancer Sci. 2011;102:166–74. [DOI] [PubMed]

102.

Zou Q, Wang X, Ren D, Hu B, Tang G, Zhang Y, et al. DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer. J Immunother Cancer. 2021;9:e002671. [DOI] [PubMed] [PMC]

103.

Ye YP, Jiao HL, Wang SY, Xiao ZY, Zhang D, Qiu JF, et al. Hypermethylation of DMTN promotes the metastasis of colorectal cancer cells by regulating the actin cytoskeleton through Rac1 signaling activation. J Exp Clin Cancer Res. 2018;37:299. [DOI] [PubMed] [PMC]

104.

Nagaraju GP, Wu C, Merchant N, Chen Z, Lesinski GB, El-Rayes BF. Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer. Cancer Lett. 2017;402:110–6. [DOI] [PubMed]

105.

Niinuma T, Kitajima H, Kai M, Yamamoto E, Yorozu A, Ishiguro K, et al. UHRF1 depletion and HDAC inhibition reactivate epigenetically silenced genes in colorectal cancer cells. Clin Epigenetics. 2019;11:70. [DOI] [PubMed] [PMC]

106.

Kong X, Chen J, Xie W, Brown SM, Cai Y, Wu K, et al. Defining UHRF1 domains that support maintenance of human colon cancer DNA methylation and oncogenic properties. Cancer Cell. 2019;35:633–48.E7. [DOI] [PubMed] [PMC]

107.

Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219–26. Erratum in: J Clin Oncol. 2010;28:4664. [DOI] [PubMed] [PMC]

108.

Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57. [DOI] [PubMed] [PMC]

109.

Etienne-Grimaldi MC, Mahamat A, Chazal M, Laurent-Puig P, Olschwang S, Gaub MP, et al. Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study. Br J Cancer. 2014;110:2728–37. [DOI] [PubMed] [PMC]

110.

Overman MJ, Morris V, Moinova H, Manyam G, Ensor J, Lee MS, et al. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget. 2016;7:67495–506. [DOI] [PubMed] [PMC]

111.

Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer. 2006;94:1087–92. [DOI] [PubMed] [PMC]

112.

Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2’-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000;60:6039–44. [PubMed]

113.

Steele N, Finn P, Brown R, Plumb JA. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer. 2009;100:758–63. [DOI] [PubMed] [PMC]

114.

Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene. 2012;31:4567–76. [DOI] [PubMed]

115.

Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 2014;5:587–98. [DOI] [PubMed] [PMC]

116.

Amatu A, Sartore-Bianchi A, Moutinho C, Belotti A, Bencardino K, Chirico G, et al. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clin Cancer Res. 2013;19:2265–72. [DOI] [PubMed]

117.

Herbst A, Vdovin N, Gacesa S, Ofner A, Philipp A, Nagel D, et al. Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer. Int J Cancer. 2017;140:2134–44. Erratum in: Int J Cancer. 2018;142:E1. [DOI] [PubMed]

118.

Bhangu JS, Beer A, Mittlböck M, Tamandl D, Pulverer W, Schönthaler S, et al. Circulating free methylated tumor DNA markers for sensitive assessment of tumor burden and early response monitoring in patients receiving systemic chemotherapy for colorectal cancer liver metastasis. Ann Surg. 2018;268:894–902. [DOI] [PubMed]

119.

Pulverer W, Kruusmaa K, Schönthaler S, Huber J, Bitenc M, Bachleitner-Hofmann T, et al. Multiplexed DNA methylation analysis in colorectal cancer using liquid biopsy and its diagnostic and predictive value. Curr Issues Mol Biol. 2021;43:1419–35. [DOI] [PubMed] [PMC]

120.

Fatemi N, Tierling S, Es HA, Varkiani M, Mojarad EN, Aghdaei HA, et al. DNA methylation biomarkers in colorectal cancer: clinical applications for precision medicine. Int J Cancer. 2022;151:2068–81. [DOI] [PubMed]

121.

Maes K, Mondino A, Lasarte JJ, Agirre X, Vanderkerken K, Prosper F, et al. Epigenetic modifiers: anti-neoplastic drugs with immunomodulating potential. Front Immunol. 2021;12:652160. [DOI] [PubMed] [PMC]

122.

Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A. 2014;111:11774–9. [DOI] [PubMed] [PMC]

123.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20. [DOI] [PubMed] [PMC]

124.

Kim YH, Kakar S, Cun L, Deng G, Kim YS. Distinct CpG island methylation profiles and BRAF mutation status in serrated and adenomatous colorectal polyps. Int J Cancer. 2008;123:2587–93. [DOI] [PubMed]

125.

Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, et al. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020;12:eaax7533. Erratum in: Sci Transl Med. 2020;12:eabc1078. [DOI] [PubMed]

126.

Savio AJ, Mrkonjic M, Lemire M, Gallinger S, Knight JA, Bapat B. The dynamic DNA methylation landscape of the mutL homolog 1 shore is altered by MLH1-93G>A polymorphism in normal tissues and colorectal cancer. Clin Epigenetics. 2017;9:26. [DOI] [PubMed] [PMC]

127.

Ye W, Ling S, Liu RY, Pan ZZ, Wang G, Gao S, et al. Exome sequencing reveals the genetic landscape and frequent inactivation of PCDHB3 in Chinese rectal cancers. J Pathol. 2018;245:222–34. [DOI] [PubMed]

128.

Yan W, Wu K, Herman JG, Xu X, Yang Y, Dai G, et al. Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer. Clin Epigenetics. 2018;10:69. [DOI] [PubMed] [PMC]

129.

Zheng R, Gao D, He T, Zhang M, Zhang X, Linghu E, et al. Methylation of DIRAS1 promotes colorectal cancer progression and may serve as a marker for poor prognosis. Clin Epigenetics. 2017;9:50. [DOI] [PubMed] [PMC]

130.

Shuai W, Wu J, Chen S, Liu R, Ye Z, Kuang C, et al. SUV39H2 promotes colorectal cancer proliferation and metastasis via tri-methylation of the SLIT1 promoter. Cancer Lett. 2018;422:56–69. [DOI] [PubMed]

131.

Vedeld HM, Nesbakken A, Lothe RA, Lind GE. Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer. Clin Epigenetics. 2018;10:70. [DOI] [PubMed] [PMC]

132.

Pan Q, Zhong S, Wang H, Wang X, Li N, Li Y, et al. The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability. Mol Cell. 2021;81:2736–51.E8. [DOI] [PubMed]

133.

Yin K, Lee J, Liu Z, Kim H, Martin DR, Wu D, et al. Mitophagy protein PINK1 suppresses colon tumor growth by metabolic reprogramming via p53 activation and reducing acetyl-CoA production. Cell Death Differ. 2021;28:2421–35. [DOI] [PubMed] [PMC]

134.

Neitzel C, Demuth P, Wittmann S, Fahrer J. Targeting altered energy metabolism in colorectal cancer: oncogenic reprogramming, the central role of the TCA cycle and therapeutic opportunities. Cancers (Basel). 2020;12:1731. [DOI] [PubMed] [PMC]

135.

Reckzeh ES, Karageorgis G, Schwalfenberg M, Ceballos J, Nowacki J, Stroet MCM, et al. Inhibition of glucose transporters and glutaminase synergistically impairs tumor cell growth. Cell Chem Biol. 2019;26:1214–28.E25. [DOI] [PubMed]

136.

Li R, Grimm SA, Mav D, Gu H, Djukovic D, Shah R, et al. Transcriptome and DNA methylome analysis in a mouse model of diet-induced obesity predicts increased risk of colorectal cancer. Cell Rep. 2018;22:624–37. [DOI] [PubMed] [PMC]

137.

Wang T, Maden SK, Luebeck GE, Li CI, Newcomb PA, Ulrich CM, et al. Dysfunctional epigenetic aging of the normal colon and colorectal cancer risk. Clin Epigenetics. 2020;12:5. [DOI] [PubMed] [PMC]

138.

Tiffon C. The impact of nutrition and environmental epigenetics on human health and disease. Int J Mol Sci. 2018;19:3425. [DOI] [PubMed] [PMC]

139.

Bekdash RA. Early life nutrition and mental health: the role of DNA methylation. Nutrients. 2021;13:3111. [DOI] [PubMed] [PMC]

140.

Łoboś P, Regulska-Ilow B. Link between methyl nutrients and the DNA methylation process in the course of selected diseases in adults. Rocz Panstw Zakl Hig. 2021;72:123–36. [DOI] [PubMed]

141.

Boughanem H, Hernandez-Alonso P, Tinahones A, Babio N, Salas-Salvadó J, Tinahones FJ, et al. Association between serum vitamin B12 and global DNA methylation in colorectal cancer patients. Nutrients. 2020;12:3567. [DOI] [PubMed] [PMC]

142.

Noreen F, Röösli M, Gaj P, Pietrzak J, Weis S, Urfer P, et al. Modulation of age- and cancer-associated DNA methylation change in the healthy colon by aspirin and lifestyle. J Natl Cancer Inst. 2014;106:dju161. [DOI] [PubMed] [PMC]

143.

Zhou X, Wang L, Xiao J, Sun J, Yu L, Zhang H, et al. Alcohol consumption, DNA methylation and colorectal cancer risk: results from pooled cohort studies and Mendelian randomization analysis. Int J Cancer. 2022;151:83–94. [DOI] [PubMed] [PMC]

144.

Al Jowf GI, Snijders C, Rutten BPF, de Nijs L, Eijssen LMT. The molecular biology of susceptibility to post-traumatic stress disorder: highlights of epigenetics and epigenomics. Int J Mol Sci. 2021;22:10743. [DOI] [PubMed] [PMC]

145.

Mehta D, Miller O, Bruenig D, David G, Shakespeare-Finch J. A systematic review of DNA methylation and gene expression studies in posttraumatic stress disorder, posttraumatic growth, and resilience. J Trauma Stress. 2020;33:171–80. [DOI] [PubMed]